In the area of cancer nanomedicine, we have drawn long-standing collaborative projects with various qroups in the neighboring institutes In a DBT funded collaborative project with Bombay college of Pharmacy, we developed sugar conjugated nano-formulation for intraocular carboplatin formulation in orthotopic retinoblastoma mouse model. In another collaboration with Chemical Engineering dept. |T-B, we have developed mesoporous silica nanoparticles (MSN) loaded Gemcitabine and/or curcumin for treatment of pancreatic cancer.

The HER2 receptor is a tyrosine kinase that drives breast cancer commonly designated as HER2+ve subtype. In these patients, the HER2 receptor protein is either overexpressed and/or harbor mutations occurring In various segments of this receptor. We are specifically stucying how the mutations occurring in the direrization domain might alter the dynamics of signaling, thereby promoting toahe reSIStaNCE HER2 targeted therapies. Understanding the downstream signaling switches that occur in presence of specific acquired mutations would help develop effective precision treatment.

Our group has long drawn interest in Cancer Nanomedicines which provide alternative treatment solutions for otherwise difficult to treat cancers. To develop various bio-functionalized, tumor-targeted nanomedicine materials for cancer therapy, we are actively engaged in multiple collaborative projects. In one promising line of work done in collaboration with NanoBios Lab at IlT-B, we have tested multiple biocompatible gold-nanospheres (Au-NS) nanomaterial for photothermal therapy (PTT). This method shows exceptional therapy efficacy in vivo.